A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer.

Trial Profile

A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs AZD 4877 (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2012 Planned number of patients changed from 50 to 54 as reported by German Clinical Trials Register.
    • 29 Aug 2012 New source identified and integrated (DRKS00004052: German Clinical Trials Register).
    • 23 Nov 2010 Additional lead trial investigator (Robert Jones) added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top